Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: A joint consensus.
Journal
Hepatology communications
Journal Volume
8
Journal Issue
11
Start Page
e0571
ISSN
2471-254X
Date Issued
2024-11-01
Author(s)
Huang, Jee-Fu
Yeh, Ming-Lun
Shen, Feng-Chih
Tai, Chi-Ming
Chen, Jung-Fu
Huang, Yi-Hsiang
Hsu, Chih-Yao
Cheng, Pin-Nan
Lin, Ching-Ling
Hung, Chao-Hung
Chen, Ching-Chu
Lee, Mei-Hsuan
Lee, Chun-Chuan
Lin, Chih-Wen
Liu, Sung-Chen
Yang, Hwai-I
Chien, Rong-Nan
Kuo, Chin-Sung
Peng, Cheng-Yuan
Chang, Ming-Ling
Huang, Chung-Feng
Yang, Yi-Sun
Lin, Han-Chieh
Ou, Horng-Yih
Chuang, Wan-Long
Huang, Chien-Ning
Yu, Ming-Lung
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide, affecting >30% of the global population. Metabolic dysregulation, particularly insulin resistance and its subsequent manifestation as type 2 diabetes mellitus, serves as the fundamental pathogenesis of metabolic liver disease. Clinical evidence of the recent nomenclature evolution is accumulating. The interaction and impacts are bidirectional between MASLD and diabetes in terms of disease course, risk, and prognosis. Therefore, there is an urgent need to highlight the multifaceted links between MASLD and diabetes for both hepatologists and diabetologists. The surveillance strategy, risk stratification of management, and current therapeutic achievements of metabolic liver disease remain the major pillars in a clinical care setting. Therefore, the Taiwan Association for the Study of the Liver (TASL), Taiwanese Association of Diabetes Educators, and Diabetes Association of the Republic of China (Taiwan) collaboratively completed the first guidance in patients with diabetes and MASLD, which provides practical recommendations for patient care.
SDGs
Type
journal article